ARDC Research Link Australia Research Link Australia   BETA Research
Link
Australia
  • ARDC Newsletter Subscribe
  • Contact Us
  • Home
  • About
  • Feedback
  • Explore Collaborations
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation

Need help searching? View our Search Guide.

Advanced Search

Current Selection
Research Topic : LIMBAL ALLOGRAFT
Clear All
Filter by Field of Research
Medical and Health Sciences (5)
Dermatology (3)
Nephrology and Urology (3)
Optometry and Ophthalmology (3)
Clinical chemistry (incl. diagnostics) (1)
Innate Immunity (1)
Nephrology And Urology (1)
Orthopaedics (1)
Filter by Socio-Economic Objective
Search did not return any results.
Filter by Funding Provider
National Health and Medical Research Council (22)
Filter by Status
Closed (22)
Filter by Scheme
NHMRC Project Grants (14)
NHMRC Postgraduate Scholarships (5)
Project Grants (2)
Career Development Fellowships (1)
Filter by Country
Australia (1)
Filter by Australian State/Territory
SA (1)
VIC (1)
  • Researchers (0)
  • Funded Activities (22)
  • Organisations (0)
  • Funded Activity

    Transplantation Of Corneal And Limbal Stem Cell Allografts

    Funder
    National Health and Medical Research Council
    Funding Amount
    $533,195.00
    More information
    Funded Activity

    Transplantation For The Treatment Of Corneal Disease

    Funder
    National Health and Medical Research Council
    Funding Amount
    $298,586.00
    More information
    Funded Activity

    Lentivirus-mediated Gene Transfer To The Eye

    Funder
    National Health and Medical Research Council
    Funding Amount
    $519,295.00
    Summary
    Blindness exerts major physical, emotional and economic constraints and hardship upon the sufferer. Transplant surgery can restore vision to many people who are visually impaired as a result of disease affecting the front of the eye. The transplant itself is taken from the eye of a person who has died, after consent from the donor's family. Our goal is to improve the outcome for patients who require transplants of tissue to the front of the eye, in order to restore their vision or to relieve pai .... Blindness exerts major physical, emotional and economic constraints and hardship upon the sufferer. Transplant surgery can restore vision to many people who are visually impaired as a result of disease affecting the front of the eye. The transplant itself is taken from the eye of a person who has died, after consent from the donor's family. Our goal is to improve the outcome for patients who require transplants of tissue to the front of the eye, in order to restore their vision or to relieve pain. Our work is predicated on the finding that unwanted immune responses are the major cause of graft failure in such patients. The recipient recognizes the grafted tissue as being foreign, and rejects it. Treatment with conventional systemic drugs appears to hold little promise for further improvements in outcome, but gene therapy applied to the donor tissue may provide a safe and effective way of reducing transplant failure. Gene therapy can be undertaken on the donor tissue in the laboratory, prior to transplantation surgery. In this project, we will assess the suitability of a new method of modifying the transplant. All of the work will be performed on the laboratory bench, or in experimental animals.
    Read more Read less
    More information
    Funded Activity

    Cross Reactivity By Antiviral Cytotoxic T Lymphocytes With Alloantigens & Its Implication To Allograft Rejection

    Funder
    National Health and Medical Research Council
    Funding Amount
    $425,000.00
    More information
    Funded Activity

    Anti-Gal Antibody Mediated Allograft Rejectin In Gal Knockout Mice: A Model Of Delayed Xenograt Rejection Ac

    Funder
    National Health and Medical Research Council
    Funding Amount
    $79,641.00
    More information
    Funded Activity

    Antibody Dependent Cell-mediated Allograft Rejection: A Model Of Xenograft Rejection

    Funder
    National Health and Medical Research Council
    Funding Amount
    $161,281.00
    More information
    Funded Activity

    Macrophage Participation In Renal Allograft Rejection-focus On The Role Of Interleukin-18.

    Funder
    National Health and Medical Research Council
    Funding Amount
    $98,238.00
    More information
    Funded Activity

    Therapeutic Ocular Surface Medium For Dry Eye And Persistent Epithelial Defect

    Funder
    National Health and Medical Research Council
    Funding Amount
    $53,538.00
    More information
    Funded Activity

    Therapeutic Ocular Surface Medium For Dry Eye & Persistent Epithelial Defect: In Vivo & In Vitro Studies

    Funder
    National Health and Medical Research Council
    Funding Amount
    $9,900.00
    More information
    Funded Activity

    Interplay Between Innate And Adaptive Immunity In Kidney Allograft Rejection

    Funder
    National Health and Medical Research Council
    Funding Amount
    $403,101.00
    Summary
    Acute allograft rejection (AR) still occurs in up to 40% of patients and is the major cause of graft loss during the first year after kidney transplantation. Even when treated, AR causes graft damage and is a major risk factor for premature graft loss due to chronic allograft nephropathy. Graft loss due to rejection returns the patient to dialysis and thus incurs medical costs in excess of $50,000 p.a. and reduces the duration and quality of life of the patient. Thus, AR directly and indirectly .... Acute allograft rejection (AR) still occurs in up to 40% of patients and is the major cause of graft loss during the first year after kidney transplantation. Even when treated, AR causes graft damage and is a major risk factor for premature graft loss due to chronic allograft nephropathy. Graft loss due to rejection returns the patient to dialysis and thus incurs medical costs in excess of $50,000 p.a. and reduces the duration and quality of life of the patient. Thus, AR directly and indirectly places a major burden upon patients, transplant services and the Australian community. AR occurs because of an adaptive alloimmune response mediated by T cells. The allografts also elicit an innate response and recent work has demonstrated both the prominence of the innate response and its essential role in facilitating adaptive alloimmunity. T cells are a component of the adaptive response and are prominent within rejecting allografts. NKG2D and toll like receptors (TLRs) are components of innate immune system. Our data demonstrates that ischemia reperfusion injury (IRI) causes upregulation of NKG2D ligand RAE-1 by kidney cells and TLR4 expression in kidney IRI and AR and that NKG2D expression is upregulated during kidney AR, and is expressed by intragraft CD8+ cells. Our results indicate that an interaction between innate and adaptive immunity may promote AR. We aim to determine whether: 1) TLR4 is required for the development of IRI to kidney and RAE-1 expression. 2) blockade of the interaction between NKG2D and its ligand RAE-1 expressed on the graft can attenuate AR and consequently prolong graft survival. 3) combined blockade of innate plus adaptive co-stimulatory molecules is more effective than either alone. This work will dissect the key interactions between innate and adaptive immunity in the allograft response and identify new targets for the prevention and treatment of allograft rejection.
    Read more Read less
    More information

    Showing 1-10 of 22 Funded Activites

    • 1
    • 2
    • 3
    Advanced Search

    Advanced search on the Researcher index.

    Advanced search on the Funded Activity index.

    Advanced search on the Organisation index.

    National Collaborative Research Infrastructure Strategy

    The Australian Research Data Commons is enabled by NCRIS.

    ARDC CONNECT NEWSLETTER

    Subscribe to the ARDC Connect Newsletter to keep up-to-date with the latest digital research news, events, resources, career opportunities and more.

    Subscribe

    Quick Links

    • Home
    • About Research Link Australia
    • Product Roadmap
    • Documentation
    • Disclaimer
    • Contact ARDC

    We acknowledge and celebrate the First Australians on whose traditional lands we live and work, and we pay our respects to Elders past, present and emerging.

    Copyright © ARDC. ACN 633 798 857 Terms and Conditions Privacy Policy Accessibility Statement
    Top
    Quick Feedback